Company ProfilePremium

SPI Pharma

Company Profile Analysis

ESOMAR 23 Corporate BadgeISO Certifications Badge
SPI Pharma - Chemicals & Materials showcase

Year Founded & Workforce

1994

300 Employees

Industry

Chemicals & Materials
S

SPI Pharma Employee Contacts

7 verified contactsNames, job titles, seniority and locations

View Employee Contacts

SPI Pharma Overview

Company Headquarters: Texas, US

Founded: 1994

Workforce: ~300

Company Working: SPI Pharma (SPI) is a subsidiary company of Associated British Foods plc (ABF), it is a part of ABF Ingredients division. SPI Pharma offers a wide range of magnesium hydroxide powders that vary in particle size and density. The company provides innovative solutions for the pharmaceutical and nutritional industries. SPI’s product line comprises antacid actives, compressible calcium powders, drug delivery systems, vaccine adjuvants, functional excipients, and taste-masked actives. The company distributes and sells its products through distributors and agents in North America, Europe, and the Middle East & Africa. The company has operations in France, the US, and India. SPI reported a sale of USD 139.31 million by the end of 2018.

Strategy

SPI focuses on developing technologically advanced products and delivering innovative products to meet the pharmaceutical industry demand, attaining a competitive edge. Also, the company emphasizes on the production of chemicals at a competitive cost.

Company Snapshot

$17,650.7M

Revenue

300

Employees

1994

Founded

Texas, US

Headquarters

SWOT Analysis

Strengths

  • Significant revenue growth in 2018
  • Wide geographic presence

Weaknesses

  • Dependent on raw materials suppliers

Opportunities

  • Business expansion
  • New Product Launches

Threats

  • Fluctuating currency exchange rates

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Product Offering

  • SPI Pharma

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

By Business Segment: SBU breakup-0 rose from USD 17,650.7 Mn in 2016 to USD 19,776 Mn in 2018.
SPI Pharma — By Business Segment
Series (USD Mn)201620172018
SBU breakup-017,650.719,65719,776

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.